Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of -223.06% is 158% below its 5-year average of -86.43%, near the low end of its 5-year range (-275.12%–-12.44%).
As of the fiscal period ended Tuesday, June 30, 2026. 16.48% below its 12-month average of -191.49%.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -223.06%.
RETURN ON INVESTED CAPITAL (ROIC)
-223.06%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-191.49%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-120.54%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
-86.43%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
-104.09%
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
-16.48%
CURRENT VS 3Y AVG
-85.04%
CURRENT VS 5Y AVG
-158.08%
CURRENT VS 10Y AVG
-114.29%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-35.66%
median of 837 covered companies
CURRENT VS SECTOR MEDIAN
-525.51%
vs the sector median at left
Insight Molecular Diagnostics Inc.
Market Cap
$109.14M
Return on Invested Capital (ROIC)
-223.06%
TTM Avg
-191.49%
3Y Avg
-120.54%
5Y Avg
-86.43%
Market Cap
$110.30M
Return on Invested Capital (ROIC)
-97.99%
TTM Avg
-45.11%
3Y Avg
-60.38%
5Y Avg
-60.38%
Market Cap
$107.17M
Return on Invested Capital (ROIC)
-6.84%
TTM Avg
-23.14%
3Y Avg
-32.81%
5Y Avg
-31.36%
Market Cap
$107.09M
Return on Invested Capital (ROIC)
-101.30%
TTM Avg
-45.83%
3Y Avg
-127.78%
5Y Avg
-123.84%
Market Cap
$106.98M
Return on Invested Capital (ROIC)
-34.77%
TTM Avg
-10.04%
3Y Avg
-11.68%
5Y Avg
-11.21%
Market Cap
$106.96M
Return on Invested Capital (ROIC)
-352.19%
TTM Avg
-1462.52%
3Y Avg
-874.13%
5Y Avg
-711.22%
Market Cap
$106.93M
Return on Invested Capital (ROIC)
-73.94%
TTM Avg
-76.71%
3Y Avg
-67.16%
5Y Avg
-152.71%
Market Cap
$106.52M
Return on Invested Capital (ROIC)
-92.16%
TTM Avg
-430.04%
3Y Avg
-259.02%
5Y Avg
-188.28%
Market Cap
$112.57M
Return on Invested Capital (ROIC)
-87.72%
TTM Avg
-74.88%
3Y Avg
-52.32%
5Y Avg
-62.32%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Insight Molecular Diagnostics Inc. (IMDX) | $109.14M | -223.06% | -191.49% | -120.54% | -86.43% |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $110.30M | -97.99% | -45.11% | -60.38% | -60.38% |
| Apyx Medical Corporation (APYX)vs › | $107.17M | -6.84% | -23.14% | -32.81% | -31.36% |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $107.09M | -101.30% | -45.83% | -127.78% | -123.84% |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $106.98M | -34.77% | -10.04% | -11.68% | -11.21% |
| Outlook Therapeutics, Inc. (OTLK)vs › | $106.96M | -352.19% | -1462.52% | -874.13% | -711.22% |
| Vivani Medical, Inc. (VANI)vs › | $106.93M | -73.94% | -76.71% | -67.16% | -152.71% |
| Immunic, Inc. (IMUX)vs › | $106.52M | -92.16% | -430.04% | -259.02% | -188.28% |
| Caribou Biosciences, Inc. (CRBU)vs › | $112.57M | -87.72% | -74.88% | -52.32% | -62.32% |
| Unicycive Therapeutics, Inc. (UNCY)vs › | $112.94M | -62.15% | -258.93% | -258.93% | -190.57% |
ROIC
-223.1%
ROE
N/A
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | -223.06% |
| 2026-03-31 | -144.86% |
| 2025-12-31 | -275.12% |
| 2025-09-30 | -169.02% |
| 2025-06-30 | -145.41% |
| 2025-03-31 | -115.58% |
| 2024-12-31 | -219.52% |
| 2024-09-30 | -71.32% |
| 2024-06-30 | -54.19% |
| 2024-03-31 | -64.25% |
| 2023-12-31 | -37.13% |
| 2023-09-30 | -28.01% |
| 2023-06-30 | -19.60% |
| 2023-03-31 | -12.44% |
| 2022-12-31 | -20.45% |
| 2022-09-30 | -29.11% |
| 2022-06-30 | -34.25% |
| 2022-03-31 | -49.11% |
| 2021-12-31 | -50.57% |
| 2021-09-30 | -28.49% |
| 2021-06-30 | -23.53% |
| 2021-03-31 | -26.71% |
| 2020-12-31 | -60.86% |
| 2020-09-30 | -60.79% |
| 2020-06-30 | -51.60% |
| 2020-03-31 | -49.33% |
| 2019-12-31 | -60.47% |
| 2019-09-30 | -61.40% |
| 2019-06-30 | -47.75% |
| 2019-03-31 | -38.63% |
| 2018-12-31 | -295.64% |
| 2018-09-30 | -157.44% |
| 2018-06-30 | -213.80% |
| 2018-03-31 | -161.82% |
| 2017-12-31 | -273.16% |
| 2017-09-30 | -174.48% |
| 2017-06-30 | -166.53% |
| 2017-03-31 | -114.16% |
| 2016-12-31 | -107.38% |
| 2016-09-30 | -88.67% |
| 2016-06-30 | -242.18% |
| 2016-03-31 | -149.12% |
| 2015-12-31 | -83.68% |
| 2015-09-30 | -52.51% |
| 2015-06-30 | -86.18% |
| 2014-12-31 | -103.28% |
